In clinical trials, people lost an average of 21% of body weight in 16 months with tirzepatide medications
In the field of obesity and metabolic disease treatment, Retatrutide -the world's first triple hormone receptor agonist-has garnered widespread attention for its groundbreaking weight loss efficacy and metabolic regulation capabilities
June 2026: Sandoz announced a targeted end-of-June 2026 launch of unbranded generic semaglutide in Canada, projecting a 60% to 70% price reduction relative to branded Ozempic, the entry is the first generic semaglutide launch in a Western high-income market and establishes a pricing reference case for subsequent launches in Brazil, Mexico, and Turkey
70,71 Additionally, the exploration of GLP-1R positive allosteric modulators (PAMs) offers a new regulatory approach that could enhance the therapeutic profile of small-molecule GLP-1R agonists
This ensures safe and effective treatment that accounts for side effects and individual responses